These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10854137)

  • 21. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
    Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
    Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
    Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.
    Eskens FA; Ramos FJ; Burger H; O'Brien JP; Piera A; de Jonge MJ; Mizui Y; Wiemer EA; Carreras MJ; Baselga J; Tabernero J
    Clin Cancer Res; 2013 Nov; 19(22):6296-304. PubMed ID: 23983259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
    Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
    Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling interpatient pharmacodynamic variability of etoposide.
    Mick R; Ratain MJ
    J Natl Cancer Inst; 1991 Nov; 83(21):1560-4. PubMed ID: 1960753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
    Trocóniz IF; Cendrós JM; Soto E; Pruñonosa J; Perez-Mayoral A; Peraire C; Principe P; Delavault P; Cvitkovic F; Lesimple T; Obach R
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):239-50. PubMed ID: 22699813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.
    O'Dwyer PJ; Hudes GR; Walczak J; Schilder R; LaCreta F; Rogers B; Cohen I; Kowal C; Whitfield L; Boyd RA
    Cancer Res; 1992 Dec; 52(24):6746-53. PubMed ID: 1458462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.
    Takama H; Tanaka H; Sudo T; Tamura T; Tanigawara Y
    Cancer Chemother Pharmacol; 2001 May; 47(5):404-10. PubMed ID: 11391855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Species variation in pharmacokinetics and opsonization of palmitoyl rhizoxin (RS-1541) incorporated in lipid emulsions.
    Kurihara A; Shibayama Y; Kasuya A; Ikeda M; Hisaoka M
    J Drug Target; 1998; 5(6):491-505. PubMed ID: 9783680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment.
    Kilian R; Matschinger H; Löeffler W; Roick C; Angermeyer MC
    J Ment Health Policy Econ; 2002 Mar; 5(1):21-31. PubMed ID: 12529567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample.
    Leca FR; Marchiset-Leca D; Galeani A; Noble A; Catalin J
    Anticancer Drugs; 1998 Jul; 9(6):503-9. PubMed ID: 9877237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.
    Hirt D; Richardet JP; Urien S; Poupon J; Sogni P; Batteux F; Laurent A; Pavlovic S; Debray M; Treluyer JM; Weill B
    Ther Drug Monit; 2009 Oct; 31(5):557-65. PubMed ID: 19834427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
    Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.